Fluoropharma Medical Stock Net Income
| FPMI Stock | USD 0.0002 0.00 0.00% |
As of the 13th of February 2026, Fluoropharma Medical shows the Standard Deviation of 12.31, mean deviation of 2.98, and Variance of 151.52. Fluoropharma Medical technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Fluoropharma Medical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Fluoropharma Medical's valuation are provided below:Fluoropharma Medical does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Fluoropharma |
Fluoropharma Medical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Fluoropharma Medical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Fluoropharma Medical.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Fluoropharma Medical on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Fluoropharma Medical or generate 0.0% return on investment in Fluoropharma Medical over 90 days. FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of... More
Fluoropharma Medical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Fluoropharma Medical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Fluoropharma Medical upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1165 | |||
| Maximum Drawdown | 100.0 |
Fluoropharma Medical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fluoropharma Medical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Fluoropharma Medical's standard deviation. In reality, there are many statistical measures that can use Fluoropharma Medical historical prices to predict the future Fluoropharma Medical's volatility.| Risk Adjusted Performance | 0.1093 | |||
| Jensen Alpha | 1.42 | |||
| Total Risk Alpha | 0.4329 | |||
| Treynor Ratio | 1.22 |
Fluoropharma Medical February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1093 | |||
| Market Risk Adjusted Performance | 1.23 | |||
| Mean Deviation | 2.98 | |||
| Coefficient Of Variation | 812.4 | |||
| Standard Deviation | 12.31 | |||
| Variance | 151.52 | |||
| Information Ratio | 0.1165 | |||
| Jensen Alpha | 1.42 | |||
| Total Risk Alpha | 0.4329 | |||
| Treynor Ratio | 1.22 | |||
| Maximum Drawdown | 100.0 | |||
| Skewness | 8.12 | |||
| Kurtosis | 66.0 |
Fluoropharma Medical Backtested Returns
Fluoropharma Medical is out of control given 3 months investment horizon. Fluoropharma Medical secures Sharpe Ratio (or Efficiency) of 0.13, which denotes the company had a 0.13 % return per unit of risk over the last 3 months. We have collected data for sixteen different technical indicators, which can help you to evaluate if expected returns of 1.61% are justified by taking the suggested risk. Use Fluoropharma Medical Mean Deviation of 2.98, variance of 151.52, and Standard Deviation of 12.31 to evaluate company specific risk that cannot be diversified away. Fluoropharma Medical holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.23, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fluoropharma Medical will likely underperform. Use Fluoropharma Medical standard deviation, as well as the relationship between the maximum drawdown and day median price , to analyze future returns on Fluoropharma Medical.
Auto-correlation | 0.00 |
No correlation between past and present
Fluoropharma Medical has no correlation between past and present. Overlapping area represents the amount of predictability between Fluoropharma Medical time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Fluoropharma Medical price movement. The serial correlation of 0.0 indicates that just 0.0% of current Fluoropharma Medical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Fluoropharma Medical reported net income of (2.05 Million). This is 100.6% lower than that of the Biotechnology sector and 102.93% lower than that of the Health Care industry. The net income for all United States stocks is 100.36% higher than that of the company.
Fluoropharma Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fluoropharma Medical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Fluoropharma Medical could also be used in its relative valuation, which is a method of valuing Fluoropharma Medical by comparing valuation metrics of similar companies.Fluoropharma Medical is currently under evaluation in net income category among its peers.
Fluoropharma Fundamentals
| Return On Asset | -2.35 | |||
| Current Valuation | 9.23 M | |||
| Shares Outstanding | 34.26 M | |||
| Shares Owned By Institutions | 0.34 % | |||
| Price To Earning | (0.39) X | |||
| Price To Book | 17.76 X | |||
| EBITDA | (2.16 M) | |||
| Net Income | (2.05 M) | |||
| Cash And Equivalents | 24.72 K | |||
| Total Debt | 5.82 M | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | (0.30) X | |||
| Cash Flow From Operations | (880.12 K) | |||
| Earnings Per Share | (0.08) X | |||
| Target Price | 2.5 | |||
| Beta | -59.92 | |||
| Market Capitalization | 3.43 M | |||
| Total Asset | 334.76 K | |||
| Retained Earnings | (34.16 M) | |||
| Working Capital | (10.23 M) | |||
| Current Asset | 89 K | |||
| Current Liabilities | 10.32 M | |||
| Net Asset | 334.76 K |
About Fluoropharma Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fluoropharma Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fluoropharma Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fluoropharma Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Fluoropharma Pink Sheet
Fluoropharma Medical financial ratios help investors to determine whether Fluoropharma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Fluoropharma with respect to the benefits of owning Fluoropharma Medical security.